1. Introduction
===============

Nocardia infections are uncommon and occur mostly in patients receiving immunosuppressive therapy, organ transplant recipients, or patients infected with human immunodeficiency virus (HIV).^\[[@R1]--[@R3]\]^ Recognition of clinical isolates is vital because Nocardia species differ in the clinical spectrum of the disease they can cause and their susceptibility to antimicrobial agents.^\[[@R4]\]^ Patients with nephrotic syndrome are at a high risk of infections, for example, Cryptococcus,^\[[@R5]\]^ cytomegalovirus,^\[[@R6]\]^ toxoplasmosis,^\[[@R7]\]^ often augmented by the need for immunosuppressive therapy. Here, we present an unusual case of *Nocardia farcinica* in a patient with nephrotic syndrome on long-term corticosteroid therapy.

1.1. Case presentation
----------------------

This case report has been approved by the ethics committee of Wenzhou People\'s Hospital. A 60-year-old man was admitted to Wenzhou People\'s Hospital with a 1-week history of a subcutaneous abscess on his left lower limb. He reported no constitutional symptoms or cough and had not incurred any trauma to his leg. On admission, the patient was tachycardic but not in septic shock and had a normal systems examination. The largest subcutaneous abscess on his left lower limb was 9 cm∗10 cm and was warm and tender with intact overlying skin. He later developed further abscesses on his buttock, which were 3 cm∗3 cm in diameter.

The patient had a background history of idiopathic membranous nephropathy diagnosed on renal 14 months before admission. He was initially treated with oral methylprednisolone and Tacrolimus and achieved a complete remission. However, he later relapsed and was treated with intravenous (IV) methylprednisolone and oral Tacrolimus. Due to a lack of clinical response cyclophosphamide, he was started on oral Cyclophosphamide with an accumulated dosage of approximately 8 g. Subsequently, his renal disease was stable and the dose of oral methylprednisolone was slowly tapered down.

On blood tests, the total white cell count was 8.4 x 10\^9/L with 85.5% neutrophils and 8.1% lymphocytes. The subset of lymphocytes was almost normal: CD3+ 72.5%, CD4+ 28.6%, CD8+ 41.9%, CD4+/CD8+ 0.68, CD19+ 4.7%. His erythrocyte sedimentation rate (ESR) was elevated at 113 mm/h and C-reactive protein (CRP) was mildly elevated at 12.2 mg/L. He was found to still be nephrotic: 24-hour urine protein was raised at 8.23 g low serum albumin 18.4 g/L and cholesterol with mild renal impairment (creatinine 131 μmol/L). A computed tomography (CT) brain scan was normal while patient\'s pulmonary CT scan showed an inflammatory nodule in the upper lobe of left lung (Figure [1](#F1){ref-type="fig"}A). Ultrasound of abscesses revealed subcutaneous anechoic lesions. Blood cultures were sterile.

![Changes of the lesion after treatments. (A) The lesion in the upper lobe of left lung. (B) The lesion after treatment with TMP-SMX for 4 weeks. (C) The lesion disappeared following treatment for 4 months.](medi-96-e7211-g001){#F1}

The abscesses were drained and the patient was empirically treated with IV penicillin and oral trimethoprim-sulfamethoxazole (TMP-SMX). Culture subsequently yielded Nocardia, later identified as *N farcinica* on rRNA gene sequencing (Figure [2](#F2){ref-type="fig"}). Combination therapy of IV cefatriaxone (2 g/day) and oral TMP-SMX (1.92 g/d) was used according to drug sensitivity. The patient\'s inflammatory markers and clinical state improved and IV ceftriaxone was stopped after a 2 weeks oral. After 4 weeks, the subcutaneous abscesses disappeared and the lesion in the upper lobe of left lung had improved (Figure [1](#F1){ref-type="fig"}B). The patient was discharged on a 5-month course of oral TMP-SMX therapy. Oral methylprednisolone was stopped 2 months later and his nephrotic syndrome had improved. A follow-up CT after 3 months showed that the lesion in the upper lobe of left lung completely disappeared (Figure [1](#F1){ref-type="fig"}C) and his renal disease was stable.

![Gene sequence of *N farcinica* identified from the pus.](medi-96-e7211-g002){#F2}

2. Discussion
=============

*Nocardia farcinica* is a gram-positive, partially acid-fast, methenamine silver-positive aerobic actinomycete.^\[[@R8]\]^ The genus-Nocardia contains more than 100 species that have been identified by phenotypic and molecular methods and 16S RNA gene sequencing. Nocardiae are common in the environment and can be found worldwide in water, soil, dust, decaying vegetation, and organic matter. After inhalation or percutaneous inoculation, particularly in immunocompromised hosts, Nocardia can induce multisystem infection that can be life-threatening.^\[[@R9]\]^

*N farcinica* is characterized by higher pathogenicity ^\[[@R10]\]^ and also known to be resistant to multiple antibiotics.^\[[@R11]\]^ Timely diagnosis of the infection is important, as appropriate treatment can be lifesaving.

On the whole, early diagnosis of *N farcinica* infections remain a challenge and treatment is often empiric. This patient\'s clinical presentation was atypical.^\[[@R12]\]^ This may be explained by long-term corticosteroid therapy masking the symptoms and signs of infection. Because of the absence of history of percutaneous inoculation, it was assumed that the patient may had inhaled *N farcinica* initially with dissemination to the skin. The patient\'s blood cultures were negative, which is consistent with literature, as blood cultures for patients with Nocardia infection are rarely positive.^\[[@R13]\]^ Therefore, other tests, in this case the pus culture and gene sequencing, are necessary for diagnosis.

Standard treatment for this infection includes Ceftriaxone, Cefotaxime and, more commonly, TMP-SMX. Sulfonamides have been extensively used, with good outcomes; however, some strains of Nocardia, including *N farcinica*, may be resistant.^\[[@R13],[@R14]\]^ Although the duration of therapy required remains controversial, reports in the literature recommend 6 months to 1 year in disseminated Nocardiosis.^\[[@R15]\]^ In our case, the patient received the treatment of TMP-SMX for 6 months and was completely cured.

In conclusion, this is the first report of pulmonary and cutaneous infection caused by *N farcinica* in a patient with nephrotic syndrome. Our case highlights that even on maintenance immunosuppression, patients can develop opportunistic infections such as Nocardia and can present atypically. Early diagnosis and treatment is the key to curing such patients, which may also avoid prolonged antimicrobial therapy.

Abbreviations: *N farcinica* = *Nocardia farcinica*, TMP-SMX = trimethoprim-sulfamethoxazole.
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